Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Arun J. Sanyal; Philip N. Newsome; Iris Kliers; Laura Harms Østergaard; Michelle T. Long; Mette Skalshøi Kjær; Anna M.G. Cali; Elisabetta Bugianesi; Mary E. Rinella; Michael Roden; Vlad Ratziu

doi:10.1056/nejmoa2413258

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

A Arun J. Sanyal P Philip N. Newsome (Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King’s College London, Foundation for Liver Research and King’s College Hospital, London) I Iris Kliers (Novo Nordisk, Bagsværd, Denmark) L Laura Harms Østergaard (Novo Nordisk, Bagsværd, Denmark) M Michelle T. Long (Novo Nordisk, Bagsværd, Denmark) M Mette Skalshøi Kjær (Novo Nordisk, Bagsværd, Denmark) A Anna M.G. Cali (Novo Nordisk, Bagsværd, Denmark) E Elisabetta Bugianesi (Department of Medical Sciences, University of Turin, Turin, Italy) M Mary E. Rinella (Division of Gastroenterology, Hepatology and Nutrition, University of Chicago, Pritzker School of Medicine, Chicago) M Michael Roden (Institute for Clinical Diabetology, German Diabetes Center (Deutsches Diabetes-Zentrum), Leibniz Center for Diabetes Research at Heinrich Heine University) V Vlad Ratziu (Sorbonne Université, Hôpital Pitié–Salpêtrière, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris)

Download PDF View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal New England Journal of Medicine

Volume / Issue Vol. 392, Issue 21

Published June 05, 2025

Pages 2089-2099

DOI 10.1056/nejmoa2413258

ISSN 0028-4793

Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (11)

A

Arun J. Sanyal

P

Philip N. Newsome

Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King’s College London, Foundation for Liver Research and King’s College Hospital, London

I

Iris Kliers